Mirum Pharmaceuticals, Inc. (MIRM) earnings date
Feb 24, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | after close | 34 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Wed, Feb 25, 2026 | after close | 56 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Wed, Aug 6, 2025 | after close | 37 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | after close | 37 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | after close | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update – Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million – Received U.S. FDA approval of and launched ATEBRIOZ ® for FOP – Announced three positive readouts setting up planned regulatory submissions for LIVMARLI ® , ATEBRIOZ and brelovitug – Received U.S. FDA Orphan Drug Designation for brelovitug in HDV – Conference call to provide business updates today, November 3 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Cali" exhibit |
| Q3 FY2026 | "Q3 and Recent Highlights Commercial: Raising Full-Year Net Product Sales Guidance to $715 Million to $720 Million" exhibit |
| Q3 FY2026 | "Brelovitug AZURE-4 Phase 3 in HDV topline data expected in Q4 2026." exhibit |
| Q3 FY2026 | "Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) topline data expected in Q1 2027." exhibit |
| Q3 FY2026 | "MRM-3379 BLOOM Phase 2 in fragile X syndrome (FXS) topline data expected in 2027." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 million – Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus due to PSC – Pre-NDA meeting held for volixibat in cholestatic pruritus due to PSC; additional discussions planned before potential NDA submission, now targeted in H1 2027 – Enrollment completed in VANTAGE study of volixibat in cholestatic pruritus due to PBC; data " exhibit |
| Q2 FY2026 | "Q2 and Recent Highlights Commercial: Raising Full Year Net Product Sales Guidance to $680 Million to $700 Million" exhibit |
| Q2 FY2026 | "Brelovitug AZURE-1 and AZURE-4 Phase 3 studies in chronic hepatitis delta virus (HDV) topline results expected in Q3 and Q4 2026, respectively." exhibit |
| Q2 FY2026 | "LIVMARLI EXPAND Phase 3 study in cholestatic pruritus due to additional rare cholestatic conditions topline results expected in Q4 2026." exhibit |
| Q2 FY2026 | "Completed enrollment in the volixibat VANTAGE Phase 2b study in cholestatic pruritus due to primary biliary cholangitis (PBC); topline results expected in Q1 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MIRM
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MIRM
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MIRM/"><img src="https://veritasdata.dev/embed/MIRM.svg" alt="MIRM earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MIRM/)
Script
<script async src="https://veritasdata.dev/embed/MIRM.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MIRM"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.